LONDON, UNITED KINGDOM--(Marketwired - May 22, 2017) - Plandaí Biotechnology, Inc. (
Ezra Jones, newly-appointed Vice President of Sales and Marketing for Plandaí, commented, "Coyne Healthcare has been selling Origine 8™ in South Africa for the past several months while building distribution channels for the product throughout the world. Origine 8™ is a unique product in that it is the only catechin-based capsule on the market backed by human clinical studies that prove it has superior bioavailability. This is a newer product for Plandaí as the company has previously focused on selling Phytofare® as an ingredient rather than as a finished product.
"By further entrapping the Phytofare® in liposomes, Origine 8™ can protect the phytonutrient molecules throughout the digestive process and ensure that more of the active ingredient is absorbed into the blood stream where it remains active and at therapeutic levels for over 24 hours. No other nutraceutical extract can make this claim.
"Coyne Healthcare immediately grasped the importance of bioavailability and was an early Phytofare® adopter. It is immensely rewarding to see their growth into the U.S. and European markets, and we're pleased that our U.S. shareholders are finally going to be able to purchase products containing Phytofare® locally."
Founded in Cape Town, South Africa, Coyne Healthcare has been both developing and distributing high quality nutraceutical and food supplements since 2013. Interested parties are invited to visit Coyne Healthcare at www.coynehealthcare.co.za .
About Plandaí Biotechnology, Inc. Plandaí Biotechnology, Inc. and its subsidiaries develop highly phyto-available™ extracts. Plandaí Biotechnology controls every aspect of the process, from growing live green tea on its farms in South Africa to producing its proprietary Phytofare® extracts in-house, allowing the Company to guarantee the continuity of supply as well as quality control throughout the entire process. Targeted industries for the Company's products include beverage, cosmeceutical, wellness, nutriceutical, anti-aging, and pharmaceutical. For more information, please visit http://www.plandaibiotech.com .
Safe Harbor Statement This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance or guarantee that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to: adverse economic conditions, competition, adverse federal, state and local government regulation, international governmental regulation, inadequate capital, inability to carry out research, development and commercialization plans, loss or retirement of key executives and other specific risks. To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made. Readers are advised to review our filings with the Securities and Exchange Commission that can be accessed over the Internet at the SEC's website located at http://www.sec.gov .
CONTACT INFORMATION Contact: Investor Relations Marlin Molinaro Marmel Communications, LLC (828) 669-0616 mmolinarofc@aol.com
